2,绝大部分实验是不要真追加的,除非你受到启发,而想该投另外高档杂志—-因为你既然已经写成文章,从逻辑上肯定是一个完整的 “story” 了。
Dear reviewer:
I am very grateful to your comments for the manuscript. According with your advice, we amended the relevant part in manuscript. Some of your questions were answered below.
Dear Professor xx:
Thank you very much for your letter dated xxx xx xxxx, and the referees’ reports. Based on your comment and request, we have made extensive modification on the original manuscript. Here, we attached revised manuscript. in the formats of both PDF and MS word, for your approval. A document answering every question from the referees was also summarized and enclosed. A revised manuscript. with the correction sections red marked was attached as the supplemental material and for easy check/editing purpose. Should you have any questions, please contact us without hesitate.
Dear Editor:
Thank you for your kind letter of “……” on November **, 2005. We revised the manuscript. in accordance with the reviewers’ comments, and carefully proof-read the manuscript. to minimize typographical, grammatical, and bibliographical errors.Here below is our description on revision according to the reviewers’ comments. Part A (Reviewer 1). The reviewer’s comment: ……
The authors’ Answer: …..
2. The reviewer’s comment: ……
The authors’ Answer: …..


Part B(Reviewer 2)
1. The reviewer’s comment: ……
The authors’ Answer: …..
2. The reviewer’s comment: ……
The authors’ Answer: …..


Many grammatical or typographical errors have been revised.All the lines and pages indicated above are in the revised manuscript.
Thank you and all the reviewers for the kind advice.
Sincerely yours,
Major comments:
1. The authors need to strengthen their results by including MMP secretion, and tran-matrigel migration by a positive control progenitor cell population i.e. enriched human CD34 cells obtained from mobilized PBL, since this is a more clinically relevant source of CD34 cells which has also been shown to secrete both MMP-9 and MMP-2 (ref. 11). CD34 enriched cells from steady state peripheral blood which also secrete MMPs are also of interest.
2. In fig1Cplease specify which cell line represents MMP-negative cells. This needs to be clarified, as well as a better explanation of the method of the protocol.
3. The ELISA results are represented as “fold increase” compared to control. Instead, we suggest that standards should be used and results should be presented as absolute concentrations and only then can these results be compared to those of the zymography.
4. When discussing the results, the authors should distinguish clearly between spontaneous migration vs chemotactic migration.Furthermore, the high spontaneous migration obtained with cord blood CD34 cells should be compared to mobilized PBL CD34 enriched cells and discussed.
5. The authors claim that the clonogenic assay was performed to determine the optimum concentration for inhibition of MMP activity by phenanthroline and anti MMP-9 mAb, however they should clarify that this assay can only determine the toxicity of the inhibitors and not their optimal inhibitory concentrations.
Minor comments:
1. There are many spelling and syntax errors, especially in the results and discussion, which need correction.
a. Of special importance, is the percent inhibition of migration,which is described as percent of migration. i.e. pg 7:”Migration of CB CD34 was reduced to 73.3%?” Instead should read “Migration of CB CD34 was reduced by 73.3%?”
b. The degree symbol needs to be added to the numbers in Materials and methods.
2. It would be preferable to combine figure1Aand B, in order to confirm the reliability of fig. 1B by a positive control (HT1080).
Answer to referee 1 comment:
1. Mobilized peripheral blood is a more clinical source of CD34+ cells, so it is necessary to compare the MMP-9 secretion and trans-migration ability of CB CD34+ cells with that of mobilized PB CD34+ cells. However, we couldn’t obtain enough mobilized PB to separate PB CD34+ cells and determine the MMP-9 secretion and migration ability, so we couldn’t complement the study on PB CD34+ cells in this paper. Results obtained by Janowska-Wieczorek et al found that mobilized CD34+ cells in peripheral blood express MMP-9. Furthermore, Domenech’s study showed that MMP-9 secretion is involved in G-CSF induced HPC mobilization. Their conclusions have been added in the discussion. In our present study, our central conclusion from our data is that freshly isolated CD34+ stem/progenitor cells obtained from CB produce MMP-9.
2. MMP-9 negative cell used in fig1Cwas Jurkat cell. In zymographic analysis, MMP-9 was not detected in the medium conditioned by Jurkat cell. To exclude that the contaminating cells may play a role in the observed MMP-9 production, we screened the media conditioned by different proportion of CB mononuclear cells with MMP-9 negative cells by zymography. This result may be confusion. Actually, only by detecting the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml (since the purities of CD34+ cell are more than 90%), it could exclude the MNC role. In the revised manuscript, we only detected MMP-9 activity and antigen level in the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml. There is no MMP-9 secretion be detected in the medium conditioned by 2X105 CB MNC/ml. It excluded the possibility that the MMP-9 activity in CB CD34+ cells conditioned medium is due to the contamination by MNC.
3.In this revised paper, we have detected the MMP-9 antigen levels by using commercial specific ELISA kits (R&D System, sensitivity, 0.156ng/ml). Recombinant MMP-9 from R&D System was used as a standard. The results are expressed in the absolute concentration. The absolute concentration result has been added in the paper. As shown in Fig2, MMP-9 levels were detectable in both CB CD34+ cell conditioned medium and BM CD34+ cell conditioned medium. However, MMP-9 level was significantly higher in CB CD34+ cell conditioned medium than in BM CD34+ cell conditioned medium (0.406±0.133ng/ml versus 0.195±0.023ng/ml). Although gelatinolytic activity was not detected in media conditioned by CD34+ cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen in the BM CD34+.
4. In our study, to establish the direct link between MMP-9 and CB CD34+ cells migration, we only determined the role of MMP-9 inspontaneous migration of CB CD34+ cells, but not in chemotactic migration. Actually, regulation of hematopoietic stem cell migration, homing and anchorage of repopulation cells to the bone marrow involves a complex interplay between adhesion molecules, chemokines, cytokines and proteolytic enzymes. Results obtained by the groups of Voermans reveal that not only the spontaneous migration but also the SDF-1 induced migration of CB CD34+ cells is greatly increased in comparison to CD34+ cells from BM and peripheral blood.
5. CD34+ cells we obtained in each cord blood sample were very limited. It is not enough to screen the inhibitors concentrations to select the optimal inhibitory concentrations. In the blocking experiments, based on the concentrations used by others and the manufacturer’s recommendation, we then determined the inhibitors concentrations by excluding the toxicity of the inhibitors in that concentration, which was determined by clonogenic assay.
Minor comments:
1.The spelling and syntax errors have been checked and corrected.
2.Since the results in figure1Aand B were obtained from two separated and parallel experiments, it is not fitness to combine two figures.
Reply to the comments on JBMR-A-05-0172
Reference #10 is missing from the Introduction but used much later in the manuscript. Should these be in order used in manuscript?
The missing reference has been added into the revised manuscript.
Comment (continued):
What is the sample size for all tests performed?
The sample size for drug release and PCL degradation tests was 3.0×3.0 cm2, with a thickness of about0.1mmand a weight of about 40mg. This dada have been added into the revised manuscript.
Comment (continued):
Figure 7. There is no scientific evidence presented in the TEM figure to convince this reviewer of sub-jets. This statement on Page 9 cannot be made without clear evidence during the jet formation/separation. Figure 7 is just a large fiber and small fiber fused together, no other conclusion than this can be made.
Necessary change in the statements has been made in the revised manuscript. as well as in the referred figure accordingly.
Comment (continued):
Table 3: Need standard deviation for all values reported not just for a select few.Equation after
Table 3 not necessary. Just reference method used.
Done accordingly.
Comment (continued):
Page 11: “faster weight loss” What was the sample size? Where is the statistical analysis of this data? This reviewer does not see a significant difference in any of the data presented, thus weight loss would be considered equivalent.
Although not too much difference was seen, the conclusion that “the GS/PCL membrane exhibited a relatively faster weight loss compared with the RT/PCL membrane” was indeed applicable through “one-way analysis of variance (ANOVA)” analysis. Following the reviewer’s comment, a new sub-section has been added to the manuscript. to address the statistical analysis for the data.
Comment (continued):
Page 12: What is the sample size for release data? Looks like results based on a sample size of one? Need stand deviations on the data presented in Figure 11. Why wasn’t release
performed and compared for all electrospun conditions investigated otherwise?
Three repeated tests were performed for each set of measurements and the resulting data were averaged. As stated in the revised manuscript, each sample had a square area of 33cm2 with a slightly different thickness.Standard deviations have been added to the data shown in Fig. 11.The present manuscript. aimed to show that medical drugs can be encapsulated in ultrafine fibers through a co-axial electrospinning process. The drug release data intended to show that the encapsulation was successful. We did not consider any specific application in this preliminary paper, and in fact the two drugs were just chosen as model illustration. As such, there seemed not necessary to perform. release experiments for all of the membranes electrospun with different conditions (i.e. the core concentrations)
Comment (continued):
Table 3: Yang’s or Young’s Modulus (page 10 says Young’s).
Corrected accordingly.
Comment (continued):
Figure 11: What is the % release, not just concentration. Why just this small sample of release data? Where is the release data for the other conditions?
Unfortunately, we did not measure the amount of the shell material in obtaining the composite nanofibers. Namely, the flow rate of the shell solution during the electrospinning was not accurately controlled using an injecting pump. Hence the % release was not applicable. Please refer to the previous reply related to Page 12 and Figure 11 for the remaining comments.We acknowledge the reviewer’s comments and suggestions very much, which are valuable in improving the quality of our manuscript.
SCI生物医学英文论文发表成功经验共享系列一—(Clinical Chemistry)
将自己近10年的科研工作中有关论文整理总结发表方面的一些信息贡献出来,与大家共享!如有时间,我拟将一些已经发表的文章,按照撰写与发表的实际经历与过程,即通过案例分析每一个杂志的特色,审稿偏好,review意见及答复要点等逐一分析。可能包含的杂志系列有:nature methods,clinical chemistry,analytical chemistry,J. Clin. Immuno,Biomed. Microdev,Front. Biosci,Mol. Cell. Biochem,J. Expert,Rev. Proteomics,J biochemistry等。
本章先讲解美国Clinical Chemistry杂志,一个临床化学界的王牌杂志,近年其影响因子逐年攀升,现为7.7分。Clinical Chemistry由美国AACC每月出版,接受的文章包括与人体疾病相关的实验室研究,分析与分子诊断,仪器,资料处理,数据分析,临床研究等投稿。ISSN:0009-9147网络版ISSN:1530-8561
【出版者】American Association for Clinical Chemistry (AACC)
【收费情况】 免费,全文
Clinical Chemistry is an international journal of laboratory medicine and molecular diagnostics.Clinical Chemistry — This highly respected and often-cited scientific journal is published monthly and contains peer-reviewed methodology, research papers and other articles relevant to clinical chemistry and related laboratory sciences. Its circulation is more than 15,000.David E. Bruns, MD, Editor, (Charlottesville Office)
Sandra Weaver, Senior Editorial Assistant
Donna Brandl, Editorial Assistant
Shane P. Cyr, Editorial Assistant
Mac Fancher, Publisher, (WashingtonOffice)
Miriam Gonzalez, Publications Coordinator
Free TOC, 1965 –
Free Abstract, 1975 –
Free Fulltext, 1997 -1999
Fulltext, 1997 –
Indexed in Chemical Abstracts.
For faster access to Clinical Chemistry Online from these countries use this URL:
http://intl.clinchem.orgAustralia, Brazil, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Mexico,Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, The Netherlands, UK该杂志是由美国临床化学协会(American Association for Clinical Chemistry,AACC)主办的,于1948年成立,总部位于华盛顿,拥有1万余会员。先在网站注册,登记,按照提示一步步提供文章名称,摘要,作者姓名,所属领域,关键词,主文,图表等等。转换为PDF后就可以提交,然后给你一个查询号,接着就是等待了.
Home Author Area Reviewer Area Personal Info. ClinChem Home Sign Out Submit New Manuscript. Information for Authors Queue Summary Feedback Help FAQ
Decision Letter
[Return to Queue]
Subject: Clinical Chemistry — Manuscript. Decision
RE: Clinical Chemistry MS ID# CLINCHEM/2002/036332
Dear Dr. xxx:
Your manuscript. has been examined by two expert reviewers. Please visit to view their comments. For the reasons detailed in these comments, we cannot accept this manuscript. for publication in Clinical Chemistry in this form. Also, your Reference 28 is not formatted properly. Our Information for Authors will offer assistance with journal style; it can be found at would consider a revised version that takes these criticisms into account. If you should resubmit the paper I would also ask that you have several English speaking colleagues proof the paper for grammar and composition. Additionally, be sure to provide a detailed point-by-point response to the comments of the reviewers. Failure to do so will delay consideration of the revised manuscript.Prior to publication we require copyright releases signed by all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from Please note that all authors must sign both sections of the form. (a signature on the lower section means that all conflicts of interest have been disclosed even if there are none). Send the completed form. to us by FAX (434-979-7599).
Dr. xxx nesley
Associate Editor
P.S. You will find your revised manuscript. can be uploaded in your “Submit a Revision” queue at Please do not begin the submission of your revised manuscript. until you are ready to submit the entire manuscript. A checklist regarding requirements for submission can be found at Figures must be uploaded as Image Files in .tif or .eps files at 600 DPI. Alternatively, you may use PowerPoint software for figures but fonts must be embedded and only one image per slide, one slide per file. When uploading the revised version, please be sure to include in the “Response to Reviews” field a point-by-point list of all changes made, or your rebuttal, in response to each of the reviewers?
P.P.S. Please note that if your manuscript. has color figures, the authors are expected to bear the cost of printing them, except in the case of invited papers. The charges for these figures are $1500 for the first color figure or part of a figure, and $500 for each additional color figure or part of a figure. Authors will be billed for color publication costs unless they request that their figures be printed in black and white.
1)实验的有效性和深度(at least for a few substances of major importance
detection limits, cut-off values and specificity should have been
studied. Also the description of the assay principle is not quite
2)语言问题(The English text would have to be substantially improved)
3)核心的技术问题(A cut-off value is given for MOL but the dimension is missing. In the discussion various anecdotic reports are given for which no data are presented under results.) 重新验证讨论。 本来认为很快就可以接受了,没想到却又等了一个半月(中间发过一次信件询问)才收到回信。原来除了上次2个评委,这次又增加了一个独立审稿人。
Your revised manuscript. has been examined by the original two reviewers, plus a recommended third reviewer with special expertise in this area. Please visit to retrieve their comments. The three reviewers find merit in the work, but have numerous constructive suggestions(别害怕,其实就是几个小问题). Please consider these suggestions carefully and prepare an improved version that addresses these concerns. I have also noted that there are several color figures included in the paper, which seem to be useful only in color. Please be aware that (should your paper be accepted for publication) authors are expected to pay the costs for publication of color figures. The charge for the first color figure is $1500; subsequent figures, or parts of figures, are $500 each. Of course, if you wish to submit alternate figures in black and white (or grayscale), you may do so.
Dr. xxx
Associate Editor
P.S. You will find your revised manuscript. can be uploaded in your “Submit a Revision” queue at A checklist of requirements for submission can be found at When uploading the revised version, please be sure to include in the “Response to Reviews” field a point-by-point list of all changes made, or your rebuttal, in response to each of the reviewer suggestions. Also, please submit copyright releases for all authors. Our Authors’ Assurances and Assignment of Copyright form. can be downloaded from Please note that all authors must sign both sections of the form. Send the completed form. to us by FAX (434-979-7599).P.P.S. For figures, please submit .tif files that have a minimum resolution of 600 DPI; the width and height of the Pixels should be about 4200 x 4200. Alternatively, you may use PowerPoint for figures, but each .ppt file may contain only one slide and fonts must be embedded.
Thank you for your revised manuscript. It is acceptable and will be processed for publication. Please note that I edited the paper to remove all text related to Figure 6. The structures of the drugs are available to anyone who wants to look them up. Thus this figure will not be in the proofs that you receive.
If page proofs are returned promptly, your paper is scheduled to appear in the Oct issue.之前电子版会先在网上发布Papers in press are posted online 2-6 weeks before the issue date. Issues are scheduled to be mailed to subscribers and appear on the Internet before the first day of the issue month. The electronic version ( is published at Stanford University’s HighWire Press, where your article will be linked electronically to and from PubMed and directly to and from over 340 other journals that are on-line at Stanford.当然还要转移版权Prior to publication we require copyright releases signed by all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from Please note that all authors must sign both sections of the form. (a signature on the lower section means that all conflicts of interest have been disclosed even if there are none).
Thank you for this contribution.
Dr. xx
Associate Editor
Copyright © 2016-2017 图尼丁学术不端检测系统V1.0. 京山图尼丁信息技术有限公司 版权所有 鄂ICP备17027425号-1